International Journal of Cardiology
Volume 145, Issue 2 , Pages 391-392 , 19 November 2010

Phentermine cardiovascular safety II: Response to Yosefy Int J Cardiol. 2009 Epub Mar 19

  • Richard B. Rothman

      Affiliations

    • BeLite Medical Center, 3923 Old Lee Hwy., Ste. 61A, Fairfax, VA 22030, United States
    • ,
  • Ed J. Hendricks

      Affiliations

    • The Center for Weight Management, 2310 Professional Dr. Roseville, CA 95661, United States
    • 2621 Capitol Ave., Sacramento, CA 95816, United States
    • Corresponding Author InformationCorresponding author. The Center for Weight Management, 2310 Professional Drive, Suite 200, Roseville, CA 95661, United States. Tel.: +1 916 773 1191.

Received 4 February 2010 ,Accepted 14 February 2010.

References 

  1. Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. Int J Cardiol. 2006;106:262–263
  2. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety in response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. Int J Cardiol. 2006;106:262–263International journal of cardiology 2009 Electronic publication Feb 1
  3. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356:6–9
  4. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2b) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836–2841
  5. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719–724
  6. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused Update Incorporated into the ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease: a report of The American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;118:e523–e661
  7. Yosefy C. Response to ijc-d-08-03075 entitled “Phentermine cardiovascular safety”. Int J Cardiol. 2009;
  8. Michelena HI, Desjardins VA, Avierinos J-F, et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation. 2008;117:2776–2784
  9. Parmley LF, Manion WC, Mattingly TW. Nonpenetrating traumatic injury of the heart. Circulation. 1958;18:371–396
  10. Donnelly KB. Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases. Toxicol Pathol. 2008;36:204–217
  11. Cohen JS, Insel PA. The physicians' desk reference. Problems and possible improvements. Arch Intern Med. 1996;156:1375–1380
  12. Burkhart CG. The diminishing value of the physicians' desk reference and drug package inserts as a medical and legal standard of medical usage of pharmaceutical drugs. J Drugs Dermatol. 2005;4:414–415
  13. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med. 2001;161:1814–1824
  14. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity. 2009;17:1730–1735
  15. Rothman RB. Treatment of obesity with “Combination” pharmacotherapy. Am J Ther. 2009;e-publish ahead of print
  16. Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother. 2009;10:921–925
  17. Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009;16:353–358
  18. Rader WA, Steelman GM, Westman EC. Clinical experience using appetite suppressants and ssris. J Okla State Med Assoc. 2008;101:180–181
  19. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N Engl J Med. 1996;335:609–616
  20. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the united states: results from the surveillance of north american pulmonary hypertension. Chest. 2000;117:870–874
  21. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006;318:604–610
  22. Coats A. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(10)00127-0

doi: 10.1016/j.ijcard.2010.02.060

International Journal of Cardiology
Volume 145, Issue 2 , Pages 391-392 , 19 November 2010

Article Tools